FATE Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

1.20M

-35.58%

-0.274

-37.63%

874.10K

-46.34%

-0.282

-11.72%

874.10K

-54.16%

-0.286

-1.29%

Estimates Revision

The market is revising Upward the revenue expectations for Fate Therapeutics, Inc. (FATE) for FY2025, with the revenue forecasts being adjusted by 3.65% over the past three months. During the same period, the stock price has changed by -35.78%.

Revenue Estimates for FY2025

Revise Upward

+3.65%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+3.04%

In Past 3 Month

Stock Price

Go Down

-35.78%

In Past 3 Month

9 Analyst Rating

Wall Street analysts forecast FATE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FATE is 5.29 USD with a low forecast of 2.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

3 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

2.00

Averages

5.29

High

8.00

Current: 0.000

Low

2.00

Averages

5.29

High

8.00

H.C. Wainwright

Robert Burns

Neutral -> Buy

upgrade

2025-10-31

Reason

H.C. Wainwright

Robert Burns

Price Target

2025-10-31

upgrade

Neutral -> Buy

Reason

H.C. Wainwright analyst Robert Burns upgraded Fate Therapeutics to Buy from Neutral with a $5 price target. The firm views the early results results from Fate's FT819 in 10 heavily pretreated systemic lupus erythematosus patients as "encouraging." The firm cites the results and the stock's valuation for the upgrade.

Wedbush

Martin Fan

Neutral

Outperform

upgrade

$5 -> $7

2025-10-27

Reason

Wedbush

Martin Fan

Price Target

$5 -> $7

2025-10-27

upgrade

Neutral

Outperform

Reason

As previously reported, Wedbush analyst Martin Fan upgraded Fate Therapeutics to Outperform from Neutral with a price target of $7, up from $5. The firm sees promise for lead program FT819 with increasing evidence for durable response, high patient accessibility, and positive regulatory engagement. Based on updated results at ACR and an approaching pivotal trial in lupus, Wedbush is moving from the sidelines on Fate shares and now recommends them to investors. The firm sees upside into ASH and would be a buyer ahead of follow-up at ASH and further clinical/regulatory catalysts.

Wedbush

Neutral -> Outperform

upgrade

$5 -> $7

2025-10-27

Reason

Wedbush

Price Target

$5 -> $7

2025-10-27

upgrade

Neutral -> Outperform

Reason

Wedbush upgraded Fate Therapeutics to Outperform from Neutral with a price target of $7, up from $5.

Wells Fargo

Equal Weight

downgrade

2025-08-13

Reason

Wells Fargo

Price Target

2025-08-13

downgrade

Equal Weight

Reason

Wells Fargo lowered the firm's price target on Fate Therapeutics to $2.50 from $4 and keeps an Equal Weight rating on the shares. The firm highlights new measures implemented by Fate to extend cash runway, including seeking partnership for the CAR NK program and a 12% workforce reduction. With runway now extended through year-end 2027, Wells sees additional CAR T SLE data and regulatory alignment as next focus.

Barclays

Overweight

NULL

downgrade

$10 -> $2

2025-05-14

Reason

Barclays

Price Target

$10 -> $2

2025-05-14

downgrade

Overweight

NULL

Reason

Barclays lowered the firm's price target on Fate Therapeutics to $2 from $10 and keeps an Overweight rating on the shares following the Q1 report. The firm has "derisked" Fate's model.

Baird

Neutral

downgrade

$5 -> $4

2025-05-14

Reason

Baird

Price Target

$5 -> $4

2025-05-14

downgrade

Neutral

Reason

Baird lowered the firm's price target on Fate Therapeutics to $4 from $5 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results which met expectations.

Valuation Metrics

The current forward P/E ratio for Fate Therapeutics Inc (FATE.O) is -0.87, compared to its 5-year average forward P/E of -9.50. For a more detailed relative valuation and DCF analysis to assess Fate Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-9.50

Current PE

-0.87

Overvalued PE

3.36

Undervalued PE

-22.36

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-7.51

Current EV/EBITDA

0.15

Overvalued EV/EBITDA

4.12

Undervalued EV/EBITDA

-19.13

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

72.65

Current PS

29.71

Overvalued PS

134.10

Undervalued PS

11.20

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

FATE News & Events

Events Timeline

No data

News

6.0

2025-10-27Benzinga

Needham Maintains Hold Rating on Fate Therapeutics

9.0

2025-10-26Newsfilter

Fate Therapeutics Unveils New Clinical Findings at ACR Convergence 2025 Highlighting Immune Remodeling and Lasting Responses in Systemic Lupus Erythematosus Patients Treated with FT819 Off-the-Shelf CAR T-Cell Therapy

9.0

2025-08-14Newsfilter

Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment

People Also Watch

Frequently Asked Questions

What is Fate Therapeutics Inc (FATE) stock price today?

The current price of FATE is 1.05 USD — it has decreased -0.94 % in the last trading day.

What is Fate Therapeutics Inc (FATE)'s business?

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Its product candidates under development include FT819, FT522, FT829, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT522 is its first iPSC-derived CAR NK cell product candidate that incorporates its novel Alloimmune Defense Receptor (ADR) technology.

What is the price predicton of FATE Stock?

What is Fate Therapeutics Inc (FATE)'s revenue for the last quarter?

Fate Therapeutics Inc revenue for the last quarter amounts to 1.74M USD, decreased -43.36 % YoY.

What is Fate Therapeutics Inc (FATE)'s earnings per share (EPS) for the last quarter?

Fate Therapeutics Inc. EPS for the last quarter amounts to -0.27 USD, decreased -32.50 % YoY.

What changes have occurred in the market's expectations for Fate Therapeutics Inc (FATE)'s fundamentals?

How many employees does Fate Therapeutics Inc (FATE). have?

Fate Therapeutics Inc (FATE) has 181 emplpoyees as of January 10 2026.

What is Fate Therapeutics Inc (FATE) market cap?

Today FATE has the market capitalization of 121.12M USD.